Loading...
•
Dec 31, 2019
Celldex Q4 2019 Earnings Report
Celldex reported Q4 2019 results with a net loss, but is advancing its pipeline programs.
Key Takeaways
Celldex Therapeutics reported a net loss for Q4 2019, but is making progress with its CDX-1140, CDX-3379, and CDX-0159 programs. The company believes its cash position is sufficient to fund operations into the first quarter of 2021.
Celldex entered 2020 with momentum due to promising CDX-1140 data.
Patient recruitment is ongoing across multiple CDX-1140 expansion cohorts.
Dosing was completed in the Phase 1 healthy volunteer study of CDX-0159.
Celldex is preparing to advance CDX-527 into the clinic.
Celldex
Celldex
Forward Guidance
Celldex believes that its current cash, cash equivalents, and marketable securities are sufficient to fund planned operations into the first quarter of 2021.